Nuclear Medicine and Radiopharmaceuticals

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of nuclear medicine and radiopharmaceutical manufacturing market, in the short to mid and long term.

Chapter 3 provides a general introduction and a brief historical background of nuclear medicines and radiopharmaceuticals. It includes details on the applications of radiopharmaceuticals in the medical field, as well as various methods adopted by manufacturers for the production of radiopharmaceuticals. It also highlights the guidelines laid down by regulatory authorities for the production, packaging, labelling and storage, of radiopharmaceuticals. In addition, it features a discussion on the need for outsourcing in this field. Further, it presents the key requisites for the selection of a CMO partner and key future perspectives related to the use of radiopharmaceuticals within the nuclear medicine industry.

Chapter 4 provides a detailed overview of around 60 companies, featuring both contract service providers and in-house manufacturers that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, company size, purpose of production (fulfilling in-house requirements / for contract services), location of headquarters, location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), target therapeutic area (cardiology, oncology, neurology, thyroid and others) and services offered.

Chapter 5 provides an overview of around 70 non-industry players (academia and research institutes) that are actively involved in the production of radiopharmaceuticals. The chapter provides details on the year of establishment, purpose of production (fulfilling in-house requirements / for contract services), location of manufacturing facilities, scale of production, applications of radiopharmaceuticals (in diagnosis, therapeutics and theranostics), type of diagnostic radiopharmaceuticals (PET and SPECT) and type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others).

Chapter 6 features tabulated profiles of the mid-large sized US based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook..

Chapter 7 features tabulated profiles of the large EU based contract service providers / in-house manufacturers that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.

Chapter 8 features tabulated profiles of the mid-large sized contract service providers / in-house manufacturers based in Asia-Pacific and rest of the world, that possess the capabilities for the production of radiopharmaceuticals. Each profile presents a brief overview of the company, list of products and manufacturing facilities, recent developments and an informed future outlook.

Chapter 9 features a four-dimensional comparison of the radiopharmaceutical manufacturers, based on supplier power (year of establishment), product portfolio (number of isotopes being manufactured for various applications targeting different therapeutic areas) of the manufacturer, the scale at which they manufacture their respective products and company size. 

Chapter 10 features an analysis of recent partnerships and collaborations inked in this domain, since 2017. It includes a brief description of the partnership models (including manufacturing / supply agreement, acquisition / merger, product development agreement and commercialization agreement, R&D agreement, licensing agreement, asset acquisition, distribution agreement, clinical trial agreement, process development agreement and others) that have been adopted by the stakeholders in this domain. It also includes the analysis based on various parameters such as year of partnership, type of radioisotope involved, therapeutic area mentioned in the agreement and  application of the radioisotope mentioned in the agreement. It consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 presents a detailed discussion on the supply chain model of medical isotope Mo-99 / Tc-99m, highlighting the main steps of the supply chain, from irradiation of uranium targets in nuclear research reactors to the administration of Tc-99m to patients. Along with this, it describes the structure of the industry and product market at each step.

Chapter 12 presents an informed estimate of the current and future opportunity in the nuclear medicine and radiopharmaceutical manufacturing market, highlighting the likely growth of the market till the year 2030. The chapter presents a detailed market segmentation on the basis of target therapeutic area (cardiology, nephrology, oncology, thyroid and others), application area (diagnostic and therapeutic), type of diagnostic radiopharmaceuticals (PET and SPECT), type of therapeutic radiopharmaceuticals (alpha emitters, beta emitters and others), purpose of production (in-house / outsourcing) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world). 

Chapter 13 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with (arranged in the order of participant’s designation) James Davis (Vice President Quality / R&D, Shertech Laboratories), Andreas Fotopoulos (Professor of Nuclear Medicine, University of Ioannina Medical School), Jan Pruim (Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen), Michael van Dam (Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology) and Anonymous (ITM Isotopen Technologien München). 

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Nuclear Medicines and Radiopharmaceuticals
3.3. Historical Evolution of Radiopharmaceuticals
3.4. Applications of Radiopharmaceuticals
3.4.1. Nuclear Imaging / Diagnosis
3.4.1.1. Single Photon Emission Computed Tomography
3.4.1.2. Positron Emission Tomography
3.4.2. Therapeutic Use

3.5. Production of Radiopharmaceuticals
3.5.1. Radionuclide Generator
3.5.2. Particle Accelerator (Cyclotron)
3.5.3. Nuclear Reactor

3.6. Regulatory Framework for Radiopharmaceuticals
3.6.1. Guidelines for the Production of Radiopharmaceuticals
3.6.2. Guidelines for Labelling and Packaging of Radiopharmaceuticals
3.6.3. Guidelines for Storage of Radiopharmaceuticals

3.7. Need for Outsourcing Radiopharmaceuticals Manufacturing
3.8. Selecting a CMO Partner for Radiopharmaceuticals Manufacturing
3.9. Current Scenario and Future Prospects Related to Radiopharmaceuticals

4. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Purpose of Production
4.2.4. Analysis by Geographical Location of Headquarters
4.2.5. Analysis by Geographical Location of Manufacturing Facilities
4.2.6. Analysis by Scale of Production
4.2.7. Analysis by Application Area
4.2.8. Analysis by Type of Radioisotope
4.2.8.1. Radioisotopes for Diagnostic Use
4.2.8.2. Radioisotopes for Therapeutic Use

4.2.9 Analysis by Target Therapeutic Area
4.2.10 Analysis by Service(s) Offered

5. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS (NON-INDUSTRY PLAYERS): CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Purpose of Production
5.2.3. Analysis by Geographical Location of Manufacturing Facilities
5.2.4. Analysis by Scale of Production
5.2.5. Analysis by Application Area
5.2.6. Analysis by Type of Radioisotopes
5.2.6.1. Radioisotopes for Diagnostic Use
5.2.6.2. Radioisotopes for Therapeutic Use

6. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Cardinal Health
6.2.1. Company Overview
6.2.2. List of Products and Manufacturing Facilities
6.2.3. Recent Developments and Future Outlook 

6.3. GE Healthcare
6.3.1. Company Overview
6.3.2. List of Products and Manufacturing Facilities
6.3.3. Recent Developments and Future Outlook 

6.4. Jubilant Radiopharma
6.4.1. Company Overview
6.4.2. List of Products and Manufacturing Facilities
6.4.3. Recent Developments and Future Outlook 

6.5. Lantheus Medical Imaging
6.5.1. Company Overview
6.5.2. List of Products and Manufacturing Facilities
6.5.3. Recent Developments and Future Outlook 

6.6. Nordion
6.6.1. Company Overview
6.6.2. List of Products and Manufacturing Facilities
6.6.3. Recent Developments and Future Outlook 

6.7. SOFIE
6.7.1. Company Overview
6.7.2. List of Products and Manufacturing Facilities
6.7.3. Recent Developments and Future Outlook 

7. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Advanced Accelerator Applications
7.2.1. Company Overview
7.2.2. List of Products and Manufacturing Facilities
7.2.3. Recent Developments and Future Outlook 

7.3. SCK•CEN
7.3.1. Company Overview
7.3.2. List of Products and Manufacturing Facilities
7.3.3. Recent Developments and Future Outlook 

7.4. Curium Pharma
7.4.1. Company Overview
7.4.2. List of Products and Manufacturing Facilities
7.4.3. Recent Developments and Future Outlook 

7.5. Eckert & Ziegler
7.5.1. Company Overview
7.5.2. List of Products and Manufacturing Facilities
7.5.3. Recent Developments and Future Outlook 

7.6. PETNET Solutions
7.6.1. Company Overview
7.6.2. List of Products and Manufacturing Facilities
7.6.3. Recent Developments and Future Outlook 

8. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS IN ASIA-PACFIC AND REST OF THE WORLD
8.1. Chapter Overview
8.2. China Isotope & Radiation Corporation
8.2.1. Company Overview
8.2.2. List of Products and Manufacturing Facilities
8.2.3. Recent Developments and Future Outlook 

8.3. DuChemBio
8.3.1. Company Overview
8.3.2. List of Products and Manufacturing Facilities
8.3.3. Recent Developments and Future Outlook 

8.4. Eczacibasi-Monrol
8.4.1. Company Overview
8.4.2. List of Products and Manufacturing Facilities
8.4.3. Recent Developments and Future Outlook 

8.5. Nihon Medi-Physics
8.5.1. Company Overview
8.5.2. List of Products and Manufacturing Facilities
8.5.3. Recent Developments and Future Outlook 

8.6. Sinotau Pharmaceuticals
8.6.1. Company Overview
8.6.2. List of Products and Manufacturing Facilities
8.6.3. Recent Developments and Future Outlook 

9. NUCLEAR MEDICINE AND RADIOPHARMACEUTICALS MANUFACTURERS: COMPANY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Assumptions and Key Parameters
9.4. Four-Dimensional Bubble Analysis based on Supplier Power, Product Portfolio Strength and Manufacturing Capabilities
9.4.1. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
9.4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
9.4.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Nuclear Medicine and Radiopharmaceuticals Manufacturers: Partnerships and Collaborations
10.3.1. Analysis by Type of Partnership
10.3.2. Analysis by Year of Partnership
10.3.3. Analysis by Type of Radioisotope
10.3.4. Analysis by Target Therapeutic Area Mentioned in the Agreement
10.3.5. Analysis by Application Mentioned in the Agreement
10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Geographical Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. PRODUCTION AND SUPPLY CHAIN OF MEDICAL ISOTOPE MOLYBDENUM-99 (TECHNETIUM-99M)
11.1. Chapter Overview
11.2. Production and Use of Mo-99
11.2.1. Reactor-based Production
11.2.2. Accelerator-based Production

11.3. Supply Chain of Mo-99
11.3.1. Target Suppliers
11.3.2. Irradiation Service Providers
11.3.3. Mo-99 Suppliers
11.3.4. Technetium Generator Suppliers
11.3.5. Tc-99m End-Users

11.4. Future Prospects

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030
12.3.1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area
12.3.2. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area
12.3.3. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals
12.3.4. Nuclear Medicine and Radiopharmaceutical Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals
12.3.5. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production
12.3.6. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions

13. CONCLUDING REMARKS
13.1. Chapter Overview
13.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview

14.2. Shertech Laboratories
14.2.1. Company Snapshot
14.2.2. Interview Transcript: James Davis, Vice President Quality / R&D

14.3. University of Ioannina
14.3.1. Organization Snapshot
14.3.2. Interview Transcript: Andreas Fotopoulos, Professor of Nuclear Medicine

14.4. University Medical Center Groningen
14.4.1. Organization Snapshot
14.4.2. Interview Transcript: Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician

14.5. Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
14.5.1. Organization Snapshot
14.5.2. Interview Transcript: Michael van Dam, Professor

14.6. ITM Isotopen Technologien München
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Anonymous

15. APPENDIX 1:  TABULATED DATA 

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures 

Figure 3.1 Structure of a Radiopharmaceuticals Product
Figure 3.2 Production of Radiopharmaceuticals: Radionuclide Generator
Figure 3.3 Production of Radiopharmaceuticals: Particle Accelerator (Cyclotron)
Figure 3.4 Production of Radiopharmaceuticals: Nuclear Reactor
Figure 3.5 Geographical Distribution of Regulatory Bodies Governing the Production of Radiopharmaceuticals
Figure 3.6 Selecting a CMO Partner for Radiopharmaceuticals Production: Parameters to Consider
Figure 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Figure 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size
Figure 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Figure 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Figure 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Figure 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Figure 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Figure 4.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Figure 4.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Figure 4.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Figure 4.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 4.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 4.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Figure 4.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Figure 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Figure 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Figure 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Figure 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Figure 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Figure 5.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Figure 5.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Figure 5.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Figure 9.1 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in North America
Figure 9.2 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Europe
Figure 9.3 Company Competitiveness Analysis: Nuclear Medicine and Radiopharmaceuticals Manufacturers based in Asia-Pacific and Rest of the World
Figure 10.1 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Radioisotope
Figure 10.4 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Figure 10.5 Partnerships and Collaborations: Distribution by Application Mentioned in the Agreement
Figure 10.3 Most Active Players: Distribution by Number of Partnerships
Figure 10.4 Partnerships and Collaborations: Geographical Distribution
Figure 10.5 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 12.1 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 (USD Billion)
Figure 12.2 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Figure 12.3 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Application Area (USD Billion)
Figure 12.4 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Figure 12.5 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Figure 12.6 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Purpose of Production (USD Million)
Figure 12.7 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030: Distribution by Key Geographical Regions (USD Million)

List Of Tables

Table 3.1 List of Commonly Used SPECT Radionuclides
Table 3.2 List of Commonly Used PET Radionuclides
Table 3.3 List of Commonly Used Radionuclides for Therapeutic Applications
Table 3.4 List of Generator, Particle Accelerator (Cyclotron) and Reactor Produced Radionuclides
Table 3.5 List of FDA Approved Radiopharmaceuticals
Table 4.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Industry Players
Table 4.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Location of Manufacturing Facilities and Scale of Production
Table 4.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Application Area
Table 4.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Diagnostic Radioisotopes
Table 4.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Therapeutic Radioisotopes
Table 4.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Target Therapeutic Area
Table 4.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Information on Service(s) Offered
Table 5.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers: List of Non-Industry Players
Table 5.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Scale of Production
Table 5.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Application Area
Table 5.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Diagnostic Radioisotopes
Table 5.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Information on Therapeutic Radioisotopes
Table 6.1 Cardinal Health: Company Snapshot
Table 6.2 Cardinal Health: Products and Manufacturing Facilities
Table 6.3 Cardinal Health: Recent Developments and Future Outlook
Table 6.4 GE Healthcare: Company Snapshot
Table 6.5 GE Healthcare: Products and Manufacturing Facilities
Table 6.6 GE Healthcare: Recent Developments and Future Outlook
Table 6.7 Jubilant Radiopharma: Company Snapshot
Table 6.8 Jubilant Radiopharma: Products and Manufacturing Facilities
Table 6.9 Jubilant Radiopharma: Recent Developments and Future Outlook
Table 6.10 Lantheus Medical Imaging: Company Snapshot
Table 6.11 Lantheus Medical Imaging: Products and Manufacturing Facilities
Table 6.12 Lantheus Medical Imaging: Recent Developments and Future Outlook
Table 6.13 Nordion: Company Snapshot
Table 6.14 Nordion: Products and Manufacturing Facilities
Table 6.15 Nordion: Recent Developments and Future Outlook
Table 6.16 SOFIE: Company Snapshot
Table 6.17 SOFIE: Products and Manufacturing Facilities
Table 6.18 SOFIE: Recent Developments and Future Outlook
Table 7.1 Advanced Accelerator Applications: Company Snapshot
Table 7.2 Advanced Accelerator Applications: Products and Manufacturing Facilities
Table 7.3 Advanced Accelerator Applications: Recent Developments and Future Outlook
Table 7.4 SCK•CEN: Company Snapshot
Table 7.5 SCK•CEN: Products and Manufacturing Facilities
Table 7.6 SCK•CEN: Recent Developments and Future Outlook
Table 7.7 Curium Pharma: Company Snapshot
Table 7.8 Curium Pharma: Products and Manufacturing Facilities
Table 7.9 Curium Pharma: Recent Developments and Future Outlook
Table 7.10 Eckert & Ziegler: Company Snapshot
Table 7.11 Eckert & Ziegler: Products and Manufacturing Facilities
Table 7.12 Eckert & Ziegler: Recent Developments and Future Outlook
Table 7.13 PETNET Solutions: Company Snapshot
Table 7.14 PETNET Solutions: Products and Manufacturing Facilities
Table 7.15 PETNET Solutions: Recent Developments and Future Outlook
Table 8.1 China Isotope & Radiation Corporation: Company Snapshot
Table 8.2 China Isotope & Radiation Corporation: Products and Manufacturing Facilities
Table 8.3 China Isotope & Radiation Corporation: Recent Developments and Future Outlook
Table 8.4 DuChemBio: Company Snapshot
Table 8.5 DuChemBio: Products and Manufacturing Facilities
Table 8.6 DuChemBio: Recent Developments and Future Outlook
Table 8.7 Eczacibasi-Monrol: Company Snapshot
Table 8.8 Eczacibasi-Monrol: Products and Manufacturing Facilities
Table 8.9 Eczacibasi-Monrol: Recent Developments and Future Outlook
Table 8.10 Nihon Medi-Physics: Company Snapshot
Table 8.11 Nihon Medi-Physics: Products and Manufacturing Facilities
Table 8.12 Nihon Medi-Physics: Recent Developments and Future Outlook
Table 8.13 Sinotau Pharmaceuticals: Company Snapshot
Table 8.14 Sinotau Pharmaceuticals: Products and Manufacturing Facilities
Table 8.15 Sinotau Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1 Nuclear Medicines and Radiopharmaceuticals Manufacturing: List of Partnerships and Collaborations
Table 15.1 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Cumulative Distribution by Year of Establishment
Table 15.2 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players) Distribution by Company Size
Table 15.3 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Purpose of Production
Table 15.4 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Continent-wise)
Table 15.5 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Headquarters (Country-wise)
Table 15.6 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Geographical Location of Headquarters
Table 15.7 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Geographical Location of Manufacturing Facilities
Table 15.8 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Scale of Production
Table 15.9 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Company Size and Scale of Production
Table 15.10 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Application Area
Table 15.11 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.12 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.13 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Target Therapeutic Area
Table 15.14 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Industry Players): Distribution by Type of Service(s) Offered
Table 15.15 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Cumulative Distribution by Year of Establishment
Table 15.16 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Purpose of Production
Table 15.17 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Continent-wise)
Table 15.18 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Geographical Location of Manufacturing Facilities (Country-wise)
Table 15.19 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Scale of Production
Table 15.20 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Application Area
Table 15.21 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Diagnostic Radioisotopes
Table 15.22 Nuclear Medicine and Radiopharmaceuticals Manufacturers (Non-Industry Players): Distribution by Type of Therapeutic Radioisotopes
Table 15.23 Partnerships and Collaborations: Cumulative Distribution by Year of Partnership, 2017-2020
Table 15.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.25 Partnerships and Collaborations: Distribution by Type of Radioisotope
Table 15.26 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Table 15.27 Partnerships and Collaborations: Distribution by Application Area
Table 15.28 Most Active Players: Distribution by Number of Partnerships
Table 15.29 Partnerships and Collaborations: Geographical Distribution
Table 15.30 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.31 Overall Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Billion)
Table 15.32 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Target Therapeutic Area (USD Billion)
Table 15.33 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Application Area (USD Billion)
Table 15.34 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Diagnostic Radiopharmaceuticals (USD Billion)
Table 15.35 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Therapeutic Radiopharmaceuticals (USD Billion)
Table 15.36 Nuclear Medicine and Radiopharmaceutical Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Purpose of Production (USD Million)
Table 15.37 Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, Conservative, Base and Optimistic Scenario, 2020-2030: Distribution by Key Geographical Regions (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

1. 3D Imaging Drug Design and Development
2. ABX advanced biochemical compounds
3. Abzena
4. Advanced Accelerator Applications
5. Advanced Nuclear Medicine Ingredients
6. Ahmanson Translational Imaging Division
7. Alliance Medical
8. Alpha Tau
9. Arronax
10. ARTMS Products
11. ASAN Medical Center
12. Atlab Pharma
13. ATONCO
14. Australian Nuclear Science and Technology Organisation
15. Avid Radiopharmaceuticals
16. Bar-Ilan University
17. Bayer
18. Biomedical Research Imaging Center, UNC School of Medicine
19. Bio-Nucleonics
20. Blue Earth Diagnostics
21. Board of Radiation and Isotope Technology
22. Bracco Diagnostics
23. Bruce Power
24. BWX Technologies
25. Cameco
26. Canadian Nuclear Isotope Council
27. Cancer Targeted Technology
28. Cardinal Health
29. Center for Molecular and Genomic Imaging, UC Davis
30. Center for Neurosciences, The Feinstein Institute
31. Center for Radiochemistry Research, OHSU Knight Cardiovascular Institute
32. Center for Systems Imaging Core, Emory University
33. Centre for Advanced Imaging, The University of Queensland
34. Centre for In Vivo Imaging, Newcastle University
35. Centre for Probe Development and Commercialization
36. Cerveau Technologies
37. Chengdu Gaotong Isotope
38. Chengdu New Radiomedicine Technology
39. China Isotope & Radiation Corporation
40. Clinical Imaging Research Centre, National University of Singapore
41. Crump Cyclotron and Radiochemistry Technology Center,University of California
42. Curium Pharma
43. Cyclopharma
44. Cyclotek
45. Cyclotope Radiopharmacy
46. Cyclotron & Radiochemistry Facility, Stanford University School of Medicine
47. Cyclotron and Radiochemistry Facility, Citigroup Biomedical Imaging Center of Weill Cornell Medicine
48. Cyclotron and Radiochemistry Facility, UT Southwestern Medical Center
49. Cyclotron and Radiochemistry Laboratories, Keck School of Medicine of USC
50. Cyclotron and Radiopharmaceutical Core, Houston Methodist Research Institute
51. Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Centre
52. Cyclotron Facility, University  of Chicago
53. Cyclotron Radiochemistry Facility, MD Anderson Cancer Center
54. Department of Molecular and Medical Pharmacology, University of California
55. Department of Nuclear Medicine and PET, Liverpool Hospital
56. Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine
57. Department of Nuclear Medicine, School of Health Sciences, University of Ioannina
58. Department of Radiology & Biomedical Imaging, University of California
59. Department of Radiology, The University of Alabama at Birmingham
60. Department of Radiology, University of Colorado
61. Department of Radioplogy, Penn Medicine, University of Pennsylvania
62. Dongcheng Biochemicals
63. DuChemBio
64. Eckert & Ziegler
65. Eczacibasi-Monrol
66. Endocyte
67. Essential Isotopes
68. Framatome
69. FUJIFILM Toyama Chemical
70. FutureChem
71. GE Healthcare
72. GE Hitachi Nuclear Energy 
73. Global Medical Solutions
74. Global Morpho Pharma
75. Grupo RPH
76. HealthTrust
77. Heidelberg Pharma
78. Heidelberg University Hospital 
79. Huntsman Cancer Institute Center for Quantitative Cancer Imaging, Univeristy of Utah Health
80. IASON
81. ImaginAb
82. Imaging Facilities, The University of Manchester
83. Inserm
84. Institut National des Radioéléments
85. Institute for Energy Technology
86. Institute of Applied Radiopharmacy of Barcelona
87. Institute of Isotopes (IZOTOP)
88. Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf 
89. International Isotopes
90. IRE ELiT- Radiopharmaceuticals
91. Iso-Tex Diagnostics
92. IsoTherapeutics
93. Isotopia Molecular Imaging
94. Itelpharma
95. iThemba LABS
96. ITM Isotopen Technologien München
97. Jubilant Radiopharma
98. Kinectrics
99. Korea Insititute of Radiological & Medical Sciences
100. Kresge Cyclotron/PET Facility, Department of Radiology, University of Michigan
101. Lantheus Medical Imaging
102. Life Molecular Imaging
103. Macquarie University 
104. Mallinckrodt Institute of Radiology, PET Nuclear Pharmacy and Cyclotron Facility, Washington University
105. Mallinckrodt Nuclear Imaging
106. Map Medical Technologies
107. Mayo Clinic
108. McMaster University Cyclotron Facility
109. Medi-Radiopharma
110. Memorial Sloan Kettering Cancer Center
111. Merck
112. Micro-Rad
113. Molecular Imaging Institute (M2i)
114. NanoMab Technology
115. National Centre for Nuclear Research Radioisotope Centre (POLATOM)
116. NCMUSA
117. Nihon Medi-Physics
118. Ningbo Junan Pharmaceuticals Technology
119. Nordal Cyclotron & PET Radiochemistry,  Lawson Health Research Institute
120. Nordic Nanovector
121. Nordion
122. Norsk Medisinsk 
123. Novartis
124. NTP Radioisotopes
125. Nuclear and Energy Research Institute
126. Nuclear Medicine and Molecular Imaging, University of Groningen
127. Nuclear Medicine/Biomedical Imaging Research Core, Brigham and Women's Hospital
128. Nuclear Research Institute Rez
129. Nucleis Radiopharmaceuticals
130. OncoBeta
131. Ontario Power Generation
132. PET Center, Columbia University
133. PET Core, Gordan Center for Medical Imaging, Harvard Medical School
134. PET Pharm Biotech
135. PET Radiochemistry and Radiopharmacy, University of Oxford
136. PET Research Core, Renaissance School of Medicine, Stony Brook University
137. PET Research Facility, Wake Forest School of Medicine
138. PET Research Radiochemistry, University of Ottawa
139. PETNET Solutions
140. PetTecH Solutions
141. Piramal Imaging
142. PositronPharma
143. Premier
144. Progenics Pharmaceuticals
145. Q BioMed
146. Radboud University Medical Center
147. Radiochemistry & Molecular Imaging Probes Core Facility, Memorial Sloan Kettering Cancer Center
148. Radiochemistry Core, University of Virginia
149. Radiochemistry Core, Vanderbilt University Institute of Imaging Science
150. Radiochemistry Facility, Loma Linda University
151. Radiochemistry Unit, University of Helsinki 
152. RadioMedix
153. Radiopharmaceutical Core Facility, Case Western Reserve University 
154. Radiopharmazeutische Wissenschaften, Division of Nuclear Medicine at the Medical University of Vienna
155. RadLink Asia
156. Research Imaging Institute, University of Teaxs Health Science Center
157. Rosatom State Atomic Energy Corporation
158. ROTOP Pharmaka
159. Saskatchewan Centre for Cyclotron Sciences
160. SCK•CEN
161. Seibersdorf Laboratories
162. Shertech Nuclear
163. Sinotau Pharmaceutical
164. Societatea Nationala Nuclearelectrica
165. SOFIE
166. SpectronRx
167. SWAN Isotopen
168. Techna Institute
169. Telix Pharmaceuticals
170. The McConnell Brain Imaging Centre, University of McGrill
171. Theragnostics
172. Therapeia
173. Thunder Bay Cyclotron and Radiochemistry Laboratories, Lakehead University
174. Tong Xing
175. Toyama Chemical
176. Triad Isotopes
177. Turku PET Centre
178. United Imaging Healthcare
179. University of Melbourne
180. University of Missouri
181. University of Washington Radiochemistry Resources
182. USC Molecular Imaging Center, University of Southern California
183. Vect-Horus
184. Westinghouse Partners
185. Wolfson Brain Imaging Centre, University of Cambridge
186. Xcision
187. Y-mAbs Therapeutics
188. Zevacor Molecular
189. Zionexa